000109039 001__ 109039
000109039 005__ 20230519145414.0
000109039 0247_ $$2doi$$a10.3390/jcm10204643
000109039 0248_ $$2sideral$$a125213
000109039 037__ $$aART-2021-125213
000109039 041__ $$aeng
000109039 100__ $$aGalán Arévalo, María Sonsoles
000109039 245__ $$aPerinatal adverse effects in newborns with estimated loss of weight percentile between the third trimester ultrasound and delivery. The GROWIN study
000109039 260__ $$c2021
000109039 5060_ $$aAccess copy available to the general public$$fUnrestricted
000109039 5203_ $$aFetal growth restriction has been associated with an increased risk of adverse perinatal outcomes (APOs). We determined the importance of fetal growth detention (FGD) in late gestation for the occurrence of APOs in small-for-gestational-age (SGA) and appropriate-for-gestational-age (AGA) newborns. For this purpose, we analyzed a retrospective cohort study of 1067 singleton pregnancies. The newborns with higher APOs were SGA non-FGD and SGA FGD in 40.9% and 31.5% of cases, respectively, and we found an association between SGA non-FGD and any APO (OR 2.61; 95% CI: 1.35–4.99; p = 0.004). We did not find an increased APO risk in AGA FGD newborns (OR: 1.13, 95% CI: 0.80, 1.59; p = 0.483), except for cesarean delivery for non-reassuring fetal status (NRFS) with a decrease in percentile cutoff greater than 40 (RR: 2.41, 95% CI: 1.11–5.21) and 50 (RR: 2.93, 95% CI: 1.14–7.54). Conclusions: Newborns with the highest probability of APOs are SGA non-FGDs. AGA FGD newborns do not have a higher incidence of APOs than AGA non-FGDs, although with falls in percentile cutoff over 40, they have an increased risk of cesarean section due to NRFS. Further studies are warranted to detect these newborns who would benefit from close surveillance in late gestation and at delivery.
000109039 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000109039 590__ $$a4.964$$b2021
000109039 592__ $$a1.04$$b2021
000109039 594__ $$a4.4$$b2021
000109039 591__ $$aMEDICINE, GENERAL & INTERNAL$$b55 / 172 = 0.32$$c2021$$dQ2$$eT1
000109039 593__ $$aMedicine (miscellaneous)$$c2021$$dQ1
000109039 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000109039 700__ $$aMahillo-Fernández, Ignacio
000109039 700__ $$0(orcid)0000-0002-3007-302X$$aEsteban, Luis Mariano
000109039 700__ $$aAndeyro-García, Mercedes
000109039 700__ $$aPiñeiro Pérez, Roi
000109039 700__ $$aSaénz de Pipaón, Miguel
000109039 700__ $$0(orcid)0000-0001-9585-0187$$aSavirón-Cornudella, Ricardo$$uUniversidad de Zaragoza
000109039 7102_ $$11003$$2027$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Anatom.Embriol.Humana
000109039 773__ $$g10, 20 (2021), 4643 [14 pp.]$$pJ. clin.med.$$tJournal of Clinical Medicine$$x2077-0383
000109039 8564_ $$s1957407$$uhttps://zaguan.unizar.es/record/109039/files/texto_completo.pdf$$yVersión publicada
000109039 8564_ $$s2723875$$uhttps://zaguan.unizar.es/record/109039/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000109039 909CO $$ooai:zaguan.unizar.es:109039$$particulos$$pdriver
000109039 951__ $$a2023-05-18-13:58:26
000109039 980__ $$aARTICLE